HER2-positive gastroesophageal adenocarcinomas (GEAs) have traditionally been associated with limited treatment options and poor prognosis. In the setting of metastatic disease, the introduction of HER2-directed therapy and immunotherapy has led to a dramatic improvement in outcomes for patients. However, appropriate use of these agents requires careful assessment of potentially actionable molecular targets along the treatment continuum, and this necessitates coordination with the molecular pathology team to ensure appropriate tissue stewardship and interpretation of test reports. In this second of 2 podcasts focused on HER2-positive advanced or metastatic GEAs, Rahul Gosain, MD; and Rohit Gosain, MD, discuss the emerging use of novel anti-HER2 therapies, with an emphasis on supporting data and effective management of adverse events.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
272 of 272 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Evidence-Based Medicine & Research
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Neurosurgery
- Nuclear Medicine
- Ophthalmology
- Pediatric Hematology-Oncology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Surgical Oncology
- Urological Oncology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
- Podcast / audio
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedMar 20, 2026
-
Last day to claim creditMar 21, 2027 5 months left
-
Physicians’ Education Resource From Data to Decisions: Applying the Latest Evidence for New Targeted Therapies in HER2-Positive Gastroesophageal Adenocarcinoma
-
Physicians’ Education Resource Optimizing HER2 Testing in Gastroesophageal Adenocarcinoma: Laying the Foundation for Targeted Therapy
-
Physicians’ Education Resource Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma
-
touchIME +1 HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers
-
Medscape, LLC HER2 Evolution in Gastroesophageal Cancer: New Therapies and Optimized Outcomes
-
PVI, PeerView Institute for Medical Education Precision-Guided Interventions in HER2+ GI Tumors Expert Perspectives on Operationalizing The Latest Evidence on Antibody-Drug Conjugates For Advanced Disease
